Not recruiting
Prostate cancer
Not recruitingInvestigationalNo placebo
Study on the Safety and Feasibility of PSMA-T4 for Prostate Cancer Patients
InvestigationalNo placebo
- Substances:–
Countries:
Poland
Poland- Participants:18–64 years · 65+ years
Find therapies in clinical trials near you – page 6
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
101 trials match your criteria
Not recruiting
Prostate cancer
Not recruitingInvestigationalNo placebo
Study on Radiometabolic Therapy with 177Lu-PSMA for Patients with Advanced or Metastatic Tumors
InvestigationalNo placebo
- Substances:177LU-PSMA-I&T
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:177LU-PSMA-I&T
Not recruiting
Prostate cancer
Not recruitingRegistered drugNo placebo
Study on the Use of 18F-PSMA-1007, Piflufolastat (18F), and Gozetotide for Detecting Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients
Registered drugNo placebo
- Substances:GozetotidePiflufolastat (18F)+1
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Gozetotide
Not recruiting
Prostate cancer
Not recruitingInvestigationalNo placebo
Study on the Use of 64Cu-PSMA I&T to Detect Lymph Node Spread in Men with Newly Diagnosed Prostate Cancer Before Surgery
InvestigationalNo placebo
- Substances:64CU-PSMA I&T
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:64CU-PSMA I&T
Not recruiting
Prostate cancer+2
Not recruitingRegistered drug
Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
Registered drug
- Substances:Abiraterone AcetatePrednisone+1
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Abiraterone Acetate
Not recruiting
Prostate cancer+1
Not recruitingRegistered drugNo placebo
Study on the Safety of Lutetium (177Lu) Zadavotide Guraxetan and Radium Ra 223 Dichloride for Patients with Bone-Metastatic Prostate Cancer
Registered drugNo placebo
Countries:The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Lutetium (177Lu) Zadavotide Guraxetan
Not recruiting
Prostate cancer
Not recruitingRegistered drugNo placebo
Evaluation of PSMA PET/CT Imaging for Lymph Node Assessment in Patients with Intermediate and High-Risk Non-Metastatic Prostate Cancer Before Surgery
Registered drugNo placebo
- Substances:Gozetotide2-[[5-[3-[[6-[[(5S)-5-Carboxy-5-[[(1S)-1,3-Dicarboxypropyl]Carbamoylamino]Pentyl]Amino]-6-Oxohexyl]Amino]-3-Oxopropyl]-2-Oxidophenyl]Methyl-[2-[[5-(2-Carboxyethyl)-2-Oxidophenyl]Methyl-(Carboxylatomethyl)Amino]Ethyl]Amino]Acetate:gallium-68(3+) Hydron
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Gozetotide
Not recruiting
Prostate cancer
Not recruitingRegistered drug
Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment
Registered drug
- Substances:EnzalutamideLeuprorelin Acetate
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Enzalutamide
Not recruiting
Prostate cancer
Not recruitingRegistered drugNo placebo
Study on the Effect of Adding Leuprorelin Acetate to Radiotherapy for Patients with Oligo-recurrent Prostate Cancer with Up to 4 Metastases
Registered drugNo placebo
- Substances:Leuprorelin Acetate
Countries:The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Leuprorelin Acetate
Not recruiting
Prostate cancer
Not recruitingRegistered drug
Study on Darolutamide with Standard Therapy for Patients with High-Risk Localized Prostate Cancer
Registered drug
- Substances:Darolutamide
Countries:
Ireland
Ireland- Participants:18–64 years · 65+ years
- Substances:Darolutamide
Not recruiting
Prostate cancer
Not recruitingRegistered drugNo placebo
Study of Lutetium (177Lu) Vipivotide Tetraxetan and Ipilimumab for Men with Very High-Risk Prostate Cancer
Registered drugNo placebo
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Ipilimumab
Not recruiting
Prostate cancer
Not recruitingInvestigationalNo placebo
Study on Apalutamide with Radiotherapy and Hormone Therapy for High-Risk Prostate Cancer Patients with Rising PSA After Surgery
InvestigationalNo placebo
- Substances:Apalutamide
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Apalutamide